Glaukos (GKOS) Invested Capital (2014 - 2021)

Glaukos' (GKOS) quarterly Invested Capital came in at $279.3 million in Q2 2021, little changed on a QoQ basis from $279.0 million in Q1 2021.

Glaukos (GKOS) Invested Capital (2014 - 2021) Analysis & Trends

Glaukos (GKOS) has 5 years of Invested Capital data on file, last reported at $279.3 million in Q2 2021.

On a quarterly basis, Invested Capital changed N/A year-over-year to $279.3 million in Q2 2021; TTM through Mar 2022 was $279.3 million, a 24.13% decrease from a year earlier, with the FY2020 full-year figure at $89.2 million, changed N/A from the prior year.
Invested Capital for Q2 2021 stood at $279.3 million, roughly flat from $279.0 million in the prior quarter.
Over the last five years, Invested Capital for GKOS reached as high as $279.3 million in Q2 2021 and fell as low as $89.2 million in Q4 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Abbott Laboratories	201.40 Bn	194.75 Bn	6.27 Bn	4.41 Bn
2	Stryker	122.29 Bn	119.41 Bn	3.81 Bn	499.00 Mn
3	Medtronic	105.01 Bn	96.40 Bn	6.41 Bn	1.79 Bn
4	Boston Scientific	64.81 Bn	63.59 Bn	3.61 Bn	41.00 Mn
5	Edwards Lifesciences	55.28 Bn	51.60 Bn	1.29 Bn	-
6	Dexcom	29.06 Bn	27.94 Bn	750.30 Mn	-
7	Koninklijke Philips	29.02 Bn	25.93 Bn	2.07 Bn	1.41 Bn
8	GE HealthCare Technologies	28.27 Bn	26.20 Bn	1.98 Bn	7.00 Mn
9	Smith & Nephew	25.80 Bn	25.22 Bn	-	15.00 Mn
10	Glaukos	8.83 Bn	8.73 Bn	117.23 Mn	-

Download Data